ImmunoPrecise Reports Record Revenues and Positive Adjusted EBITDA Fiscal 2020
Reports rapid advancement of COVID-19 antibody programs; combination studies achieve nearly complete neutralization of SARS-CoV-2 VICTORIA, BC, Aug. 31, 2020 /PRNewswire/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSXV: IPA) (OTCQB: IPATF) today announced financial results…
Comments Off on ImmunoPrecise Reports Record Revenues and Positive Adjusted EBITDA Fiscal 2020